Trial · NCT01601236
Results by group285
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 285
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12 | Placebo | -24.927 | Standard Error 5.4198 | percent change | |
| Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12 | Acthar 8 Units | -20.563 | Standard Error 6.8126 | percent change | |
| Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12 | Acthar 16 Units | -17.447 | Standard Error 4.3473 | percent change | |
| Percent Change in eGFR at Visit 17 | Placebo | -20.407 | Standard Error 6.0183 | percent change | |
| Percent Change in eGFR at Visit 17 | Acthar 8 Units | -37.456 | Standard Error 7.8387 | percent change | |
| Percent Change in eGFR at Visit 17 | Acthar 16 Units | -22.097 | Standard Error 5.4619 | percent change | |
| Frequency of Patients With a Doubling of Serum Creatinine, Progression to End-stage Renal Disease (ESRD), or Death | Placebo | Visit 12 (Week 36) / Yes | 0 | Participants | |
| Frequency of Patients With a Doubling of Serum Creatinine, Progression to End-stage Renal Disease (ESRD), or Death | Acthar 8 Units | Visit 12 (Week 36) / Yes | 1 | Participants | |
| Frequency of Patients With a Doubling of Serum Creatinine, Progression to End-stage Renal Disease (ESRD), or Death | Acthar 16 Units | Visit 12 (Week 36) / Yes | 1 | Participants | |
| Frequency of Patients With a Doubling of Serum Creatinine, Progression to End-stage Renal Disease (ESRD), or Death | Placebo | Visit 12 (Week 36) / No | 10 | Participants | |
| Frequency of Patients With a Doubling of Serum Creatinine, Progression to End-stage Renal Disease (ESRD), or Death | Acthar 8 Units | Visit 12 (Week 36) / No | 6 | Participants | |
| Frequency of Patients With a Doubling of Serum Creatinine, Progression to End-stage Renal Disease (ESRD), or Death | Acthar 16 Units | Visit 12 (Week 36) / No | 15 | Participants | |
| Frequency of Patients With a Doubling of Serum Creatinine, Progression to End-stage Renal Disease (ESRD), or Death | Placebo | Visit 17 (Week 52) / Yes | 0 | Participants | |
| Frequency of Patients With a Doubling of Serum Creatinine, Progression to End-stage Renal Disease (ESRD), or Death | Acthar 8 Units | Visit 17 (Week 52) / Yes | 1 | Participants | |
| Frequency of Patients With a Doubling of Serum Creatinine, Progression to End-stage Renal Disease (ESRD), or Death | Acthar 16 Units | Visit 17 (Week 52) / Yes | 2 | Participants | |
| Frequency of Patients With a Doubling of Serum Creatinine, Progression to End-stage Renal Disease (ESRD), or Death | Placebo | Visit 17 (Week 52) / No | 10 | Participants | |
| Frequency of Patients With a Doubling of Serum Creatinine, Progression to End-stage Renal Disease (ESRD), or Death | Acthar 8 Units | Visit 17 (Week 52) / No | 6 | Participants | |
| Frequency of Patients With a Doubling of Serum Creatinine, Progression to End-stage Renal Disease (ESRD), or Death | Acthar 16 Units | Visit 17 (Week 52) / No | 14 | Participants | |
| Complete or Partial Remission of Proteinuria | Placebo | Visit 12 (Week 36) / Complete remission | 0 | Participants | |
| Complete or Partial Remission of Proteinuria | Acthar 8 Units | Visit 12 (Week 36) / Complete remission | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01601236/results